Every material Form 8-K MUSTANG BIO, INC. has filed with the SEC since December 23, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Mustang Bio said Nasdaq granted it an additional 180-calendar day period, until April 12, 2027, to regain compliance with the $1.00 minimum bid price rule after it missed the October 12, 2026 deadline. The company must close at or above $1.00 for at least 10 consecutive business days in that period, and it has said it may effect a reverse stock split if necessary. If it does not regain compliance, Nasdaq will issue a delisting notice, and the company says there is no assurance it will meet all continued listing requirements.
Nasdaq granted an additional 180-calendar day grace period, through April 12, 2027, letter dated October 13, 2026
Compliance requires a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, generally no more than 20
Company has stated it may effect a reverse stock split if necessary; failure to comply would lead to a delisting notice
Mustang Bio received a Nasdaq notice on April 15, 2026, saying its common stock closed below $1.00 per share for 30 consecutive business days, so it is not in compliance with the minimum bid price rule. The notice has no immediate effect on the stock's listing, but the company has until October 12, 2026 to regain compliance, and there is no assurance it will keep its Nasdaq listing.
Nasdaq notice received April 15, 2026; bid price closed below $1.00 for 30 consecutive business days
Compliance deadline is October 12, 2026, a 180-calendar day grace period
Compliance requires a closing bid price of at least $1.00 for a minimum of ten consecutive business days
Company may be eligible for a second 180-day period or may need a reverse stock split; no decision has been made
At its December 22, 2025 annual meeting, Mustang Bio stockholders approved all four proposals, including electing seven directors, ratifying KPMG LLP as auditor, and increasing shares under its employee stock purchase plan and 2016 Incentive Plan. Separately, the company disclosed a December 17, 2025 agreement to terminate its CD20 license with Fred Hutch Cancer Center, under which the company will pay $730,000 to extinguish about $1.4 million in payables owed to Fred Hutch.
The 2016 Incentive Plan amendment adds 2,500,000 shares, and the 2019 ESPP amendment adds 250,000 shares.
The Incentive Plan amendment received 7,664,161 votes for, 198,991 against and 4,278 abstentions.
Each of the seven director nominees received at least 7,712,919 votes for.
Under the termination agreement, Fred Hutch would pay at least 10% of consideration from any third-party CD20 license granted within three years.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MUSTANG BIO, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →